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Aim: The main purpose of this study was to estimate the SLC34A2 gene expression in normal ovary and different types of ovarian 
tumors. Methods: We have investigated SLC34A2 gene expression level in papillary serous, endometrioid, unspecified adenocar-
cinomas, benign tumors, and normal ovarian tissues using real-time PCR analysis. Differences in gene expression were calculated 
as fold changes in gene expression in ovarian carcinomas and benign tumors compared to normal ovary. Results: We have found 
that SLC34A2 gene was highly expressed in well-differentiated endometrioid and papillary serous ovarian carcinomas compared 
to low-differentiated endometrioid carcinomas, benign serous cystoadenomas and normal ovary. Analysis of SLC34A2 gene expres-
sion according to tumor differentiation level (poor- and well-differentiated) showed that SLC34A2 is up-regulated in well differen-
tiated tumors. Conclusion: Upregulation of SLC34A2 gene expression in well-differentiated tumors may reflect cell differentiation 
processes during ovarian cancerogenesis and could serve as potential marker for ovarian cancer diagnosis and prognosis. 
Key Words: NaPi2b, SLC34A2, gene expression, ovarian cancer, normal ovary.
The human sodium-dependent phosphate trans-
port protein 2b — NaPi2b, (NPTIIb, NAPI-3B, 
FLJ90534, NAPI-IIb) or solute carrier family 34 mem-
ber 2  is a transmembrane protein with at least eight 
highly hydrophobic helical regions that form channel 
structure via homodimeric assembly [1, 2]. Na/Pi-
cotransport via NaPi2b transporter is electrogenic with 
a likely stoichiometry of 3Na:1Pi [3].
NaPi2b is coded by the SLC34A2 gene and plays 
an important role in the maintenance of the overall phos-
phate homeostasis that is essential for proper cellular 
functions such as DNA synthesis, cell signaling, bone 
formation etc [3, 4]. NaPi2b is highly abundant in the 
brush-border membrane (BBM) of small intestine where 
it is involved in transcellular flux of inorganic phosphates 
via apical membrane of epithelial cells [3, 5].
Besides the small intestine, expression of NaPi2b 
has been described predominantly on mRNA level 
in some organs of mammalians including lung, pan-
creas, kidney, ovary, placenta, uterus, testis, secreting 
mammary gland, thyroid gland, salivary gland, bone, 
and epididimus [4–13] where its physiological role 
remains to be defined.
NaPi2b expression profile in normal tissues could 
be supplemented with sites of expression of MX35 an-
tigen because a molecular identity of both proteins 
recently was proved by several techniques [14]. 
MX35 antigen expression was described by immuno-
histochemical analysis with correspondent MX35 mAbs 
in several tissues of epithelial origin. These sites, along 
with the already described for NaPi2b include cervix, 
Fallopian tubes and sweat glands [15]. Impairments 
of SLC34A2 regulation and mutations in this gene 
might lead to development of different pathologies. 
For instance, several mutations of SLC34A2 gene were 
reported to be associated with testicular and pulmo-
nary alveolar microlithiasis [16–18] and downregula-
tion of the NaPi2b cotransporter was associated with 
hypophosphatemia [19, 20].
There are plenty of data about aberrant SLC34A2 ex-
pression in cancer cells. The downregulation of NaPi2b 
transporter was revealed in non-small cell lung carci-
nomas by RT-PCR analysis [21]. Recently, a strong 
overexpression of SLC34A2 in breast cancer and papil-
lary thyroid cancer was found using real-time RT-PCR 
[22–24]. Rangel et al. using SAGE and Nothern-blot 
analysis reported that SLC34A2 expression was clearly 
restricted to the ovarian tumors and certain ovarian 
cell lines but absent in normal ovarian tissues [25]. 
Using real-time RT-PCR analysis authors showed that 
NaPi2b expression in serous ovarian carcinomas was 
statistically associated with tumor grade and more 
differentiated tumors tended to express higher levels 
of SLC34A2 mRNA [25]. Papillary serous carcinomas 
are the most common ovarian tumors and represent 
about 50–60% of all epithelial ovarian cancers (EOC), 
and the remaining epithelial ovarian carcinomas exhibit 
endometrioid (25%), mucinous (4%) and clear cell 
(4%) histology [26]. It was considered that EOC may 
arise from ovarian surface epithelium (OSE) that has 
“uncommitted” phenotype and retains the capacity 
to differentiate into different types of cells in response 
to environmental signals. During ovarian carcinogen-
esis, the epithelium of ovary could differentiate into 
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fallopian tube epithelium (papillary serous tumors), en-
domethrial epithelium (endomethrioid tumors), colonic 
or endocervical epithelium (mucinous tumors) and 
component of endometriosis (clear cell tumors) [27].
 Recently we have described NaPi2b expression 
at mRNA and protein levels in different types of ovarian 
carcinomas (serous, endometrioid and mucinouse) 
using immunohistochemistry, Western-blot and 
conventional PCR analysis. We showed that NaPi2b 
protein expression detected by anti-NaPi2b mAbs [28] 
increased in well-differentiated serous and endome-
trioid tumors compared to poor-differentiated tumors 
at protein level but almost uniformly expressed in these 
ovarian tumors at mRNA level [29].
To estimate a quantative mRNA expression 
of NaPi2b cotransporter in different histological types 
of ovarian tumors and normal ovary we have performed 
investigation of the SLC34A2 gene expression using 
quantitative real-time RT-PCR analysis.
MATERIALS AND METHODS 
Tissue samples. Ovarian tissue samples, in par-
ticular, ovarian carcinomas (n = 14), benign serous 
cystoadenomas (n = 4) and normal ovarian tissues 
(n = 3) were obtained during surgical treatment of cor-
respondent patients at the National Cancer Institute 
(Kyiv, Ukraine). The mean age of patients with ovarian 
tumors was 47 years (range 22–69 years). Normal 
ovarian tissue samples (n = 3), obtained during surgi-
cal treatment of the patients with endometrial cancer 
(mean age 46 years, range 19–69 years) were used 
as the control. Tissue specimens were frozen immedi-
ately in liquid nitrogen and stored at –80 ˚ C until further 
analysis. The histological types of epithelial ovarian 
cancer and cell differentiation status were confirmed 
by histopathological examination by clinical pathomor-
phologists at the Department of Pathology, National 
Cancer Institute (Kyiv, Ukraine) according Christofer 
Fletcher’s Third Edition of Diagnoctic Histopathology 
of Tumors, 2007. The study protocol was approved 
by the Ethics Committees of the Institute of Molecular 
Biology and Genetics and National Cancer Institute.
Isolation of RNA. RNA was purified by a standard 
procedure using AGPC (acid guanidinium thiocyanate-
phenol-chlorophorm) method [30]. Tissue samples 
(100-150 mg) were homogenized in liquid nitrogen and 
mixed with 1 ml of denaturation solution (4 M guani-
dinium thiocyanate, 25 mM sodium citrate, pH 7.0, 
5% sarcosyl, 0.1 M 2-mercaptoethanol). Sequentially, 
0.1 ml of 2 M sodium acetate, pH 4, 1 ml of phenol 
(water saturated), and 0.2 ml of chloroform-isoamyl 
alcohol mixture (49:1) were added to the homogen-
ate, with thorough mixing after the addition of each 
reagent. The final suspension was shaken for 10 s and 
cooled on ice for 15 min. Samples were centrifuged 
at 10,000g for 20 min at 4 °C. The aqueous phase with 
RNA was transferred to a fresh tube and RNA was 
precipitated with 1 ml of isopropanol at -20 °C for 1 h. 
After sedimentation at 10,000g the resulting RNA pellet 
was dissolved in 0.3 ml of the same denaturation solu-
tion and precipitated with 1 volume of isopropanol at 
-20 °C for 1 h. After centrifugation for 10 min at 4 °C the 
RNA pellet was washed with 75% ethanol, sedimented, 
air dried, and dissolved in 50 μl nuclease-free water.
RNA purty and quality was confirmed by measur-
ing spectrophotometrically A260/A280 ratios, and 
by 1% agarose-formaldehyde denaturating gel elec-
trophoresis. Total RNA yield was quantitated spectro-
photometrically.
Preparation of cDNA from RNA samples. Total 
RNA (3 μg) was converted to cDNA with M-MuLV Re-
verse Transcriptase (Fermentas) at 37 °C for 60 min 
using oligo(dT)18 primers in 20 μl reaction volume 
according to the standart protocol of manufacturer.
Real-time RT-PCR analysis. Gene-spe-
cific TaqMan probes and PCR primers were de-
signed using NCBI software Primer-BLAST (URL: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Table). 
Table. Gene-specific TaqMan probes and PCR primers
Gene Oligonucleotide Oligonucleotide sequence (5’ — 3’) Length
SLC34A2 Forward primer ttg-gag-gaa-aaa-tgg-cag-gac-ag 23
Reverse primer gca-aga-gca-cca-aca-cgg-aca-g 22
Probe (FAM)cc-cga-aca-g(T-BHQ1)g-agc-
aat-gaa-gag-gac-acc
29
ACTB Forward primer ggc-acc-cag-cac-aat-gaa-g 19
Reverse primer gcc-gat-cca-cac-gga-gta-ct 20
Probe (FAM)tc-aag-atc-a(T-BHQ1)t-gct-cct-
cct-gag-cgc
26
The real-time reverse transcription-polymerase 
chain reaction (real-time RT-PCR) procedure was 
carried out in 25 μl of reaction mix containing diluted 
1:10 cDNA mixture (3 μg —  2 μl), forward and reverse 
primers (20 pmole each), gene-specific TaqMan probe 
(20 pmole), 10 x Taq Buffer (2.5 μl), 10 mM dNTP 
mix (5 nmole — 0.5 μl), Taq DNA Polymerase 5 u/μl 
(1.25 u — 0.25 μl), 25 mM MgCl2 (50 nmole — 2 μl) 
and nuclease-free water. The following thermal con-
ditions were applied: 95 °C for initial denaturation 
(30 s) and 40 cycles consisting of 95 °C denaturation 
(10s), 55 °C annealing (5 s) and 60 °C extension (60s). 
Thermal cycling and fluorescent monitoring were 
performed using iCycler iQ5 (Bio-Rad, CA, USA). 
Amplified products were separated on a 1% agarose 
gel and visualized.
Calculations. The point at which the PCR product 
is first detected above a fixed threshold, termed cycle 
threshold (Ct), was determined for each sample. When 
PCR product was not detected above a fixed threshold 
we defined its Ct as 40 (number of final PCR cycle).
To determine the quantity of gene-specific tran-
scripts present in ovarian tumor cDNA relative to nor-
mal ovarian tissue, their respective Ct values were 
first normalized by subtracting the Ct value obtained 
from the actin (ACTB) endogenous control (ΔCt = 
Ct SLC34A2 – Ct ACTB). For 3 normal ovarian cDNA 
samples normalized ΔCt was calculated as the mean 
value. The relative concentrations of gene-specific 
mRNAs in ovarian cancer cDNAs compared to normal 
ovarian tissue (ΔΔCt) were calculated by subtracting 
the normalized mean ΔCt value obtained for normal 
ovarian cDNAs from those obtained for each of 17 ovar-
ian tumor samples (ΔΔCt = ΔCt of tumor — mean ΔCt 
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for 3 normal ovaries), and the relative concentration 
was determined as 2^- ΔΔCt [31].
Immunohistochemical analysis. Representative 
sections of tumor samples were prepared from parafﬁn 
blocks and stained with hematoxylin-eosin according 
as previously described [29]. Endogenous peroxidase 
was quenched with H2O2 (3%) in 0.01% PBS. After 
blocking of nonspeciﬁc binding by avidin–biotin 
blocking solution (Vector Laboratories, Burlingame, 
CA, USA), tissue sections were incubated overnight 
at 4 °C with anti-NaPi2b mAb (10 μg/ml). Then, sec-
tions were incubated with biotinylated secondary 
antibodies for 2 h at room temperature (1 : 400, goat 
anti-mouse biotinylated IgG, Sigma), followed by incu-
bation with avidin–biotin–peroxidase complex (Vector 
Laboratories, Burlingame, CA, USA). The immune 
complexes were developed with diaminobenzidine 
solution. Hematoxylin was used for counterstaining. 
Prepared slides were examined with the use of Zeiss 
Universal microscope (Zeiss, Germany); images were 
captured using digital Axiocam software.
RESULTS
The expression of the SLC34A2 gene in ovarian car-
cinomas (n = 14), benign serous cystoadenomas (n = 4) 
and normal tissues (n = 3) was examined at mRNA level 
by real-time RT-PCR. In a panel of 14 ovarian carcino-
mas, there were 7 well-differentiated papillary serous 
tumors, 5 endometrioid tumors (2 well-differentiated 
and 3 poor-differentiated carcinomas), and 2 unspeci-
fied poor-differentiated adenocarcinomas. Differences 
in SLC34A2 gene expression were calculated as fold 
changes in gene expression in ovarian carcinomas 
and benign serous cystoadenomas compared to three 
normal ovaries (27 ov, 30 ov, and 35 ov). Since the PCR 
product in these three samples of normal ovary was not 
detected above a fixed threshold, which means that 
NaPi2b is not expressed in normal ovary or is expressed 
at very low levels we have defined it’s Ct as 40 in our 
calculations (see Materials and Methods).
During this study we observed overexpression 
of the SLC34A2 gene in all papillary serous tumors 
compared to normal ovarian tissues (30.5-398.1 with 
mean 152,9-fold increase) (Fig. 1, A). In addition, we de-
tected a heterogeneous level of the SLC34A2 gene 
expression in endometrioid tumors, unspecified poor-
differentiated adenocarcinomas and benign tumors 
compared to normal ovarian tissues (Fig. 1, B, C, and 
D). It should be noted that the level of SLC34A2 gene 
expression in benign ovarian tumors differed slightly 
compared to normal ovary, in contrast to the expression 
level of SLC34A2 gene in ovarian carcinomas where 
it differed significantly compared to normal tissues.
Figure 2 demonstrates SLC34A2 gene expression 
in the ovarian carcinoma samples grouped according 
to their differentiation level.  SLC34A2 gene was highly 
expressed in all well-differentiated papillary serous 
tumors and well-differentiated endometrioid tumor 
samples 14ov and 18ov (19.8-54.1 with mean 36.9-fold 
increase) compared to poor-differentiated endometri-
oid tumor samples 5ov, 6ov and 22ov (0.18-0.75 with 
mean 0.44-fold decrease) and poor-differentiated 
adenocarcinoma tumor sample 16ov (0.29) (Fig. 2). 
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Fig. 1. Real-time RT-PCR results for relative expression level 
of SLC34A2 in ovarian tumor cDNA samples grouped according 
to histomorphological type. The mean of SLC34A2 expression 
level in 3 normal tissues referred as 1 in all cases. A. Papillary 
serous carcinomas (8ov, 13ov, 15ov, 19ov, 21ov, 24ov, 29ov); 
B. Endometrioid carcinomas (14ov, 18ov — well-differentiated; 
5ov, 6ov, 22ov — poor-differentiated); C. Unspecified adenocar-
cinomas  (16ov, 23ov — poor-differentiated); D. Benign tumors 
(9ov, 17ov; 25ov, 28ov — serous cystoadenomas)
Data  concerning mRNA expression of SLC34A2 in se-
rous and endometrioid ovarian tumors accurately cor-
related with NaPi2b protein expression in these types 
of ovarian tumors detected by Western-blot and immu-
nohistochemical analyses in our previous investigation 
[29]. Summarizing the results we can conclude that 
SLC34A2 gene is up-regulated in well-differentiated 
ovarian carcinomas compared with poor-differentiated 
ovarian carcinomas and benign serous cystoadeno-
mas both at the mRNA and protein levels.
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Fig. 2. Real-time RT-PCR results for relative expression level 
of SLC34A2 in ovarian cancer samples grouped according to tu-
mor differentiation level. The mean of SLC34A2 expression level 
in 3 normal tissues referred as 1 in all cases. A. Poor-differentiat-
ed ovarian tumors; B. Well-differentiated ovarian tumors
Immunohistochemical analysis with anti-NaPi2b 
monoclonal antibodies in our previous investigation 
and in this study has shown that NaPi2b is expressed 
predominantly at the surface membrane (M) of cancer 
cells in well-differentiated serous and endometrioid 
ovarian carcinomas (Figures 3 a, b) [29]. In addition 
to membrane localization, in some cases we observed 
a weak NaPi2b positive staining in the cytoplasm (C) 
and the nuclei (N) of cancer cells and cells of certain 
benign tumors (Figures 3 a, b, c).
Experimental Oncology 33, 94–98, 2011 (June) 97
Fig. 3. Immunohistochemical analysis of NaPi2b expression 
in ovarian tumors: a, serous papillary carcinoma; b, well-dif-
ferentiated endometrioid carcinoma; c, serous cystadenoma. 
NaPi2b positive staining at the membrane of cells marked 
as M, in cytoplasme and in nuclei as C and N correspondently. 
Magniﬁcation x 400
DISCUSSION
In our previous study, we have analyzed NaPi2b 
expression at protein and mRNA levels in different 
types of epithelial ovarian cancer and normal ovarian 
tissues using Western blot, immunohistochemical and 
qualitative RT-PCR techniques [29]. We have shown 
a differential expression profile of NaPi2b phosphate 
transporter at protein level in various histological types 
of epithelial ovarian cancer and have not identified 
any protein expression in normal ovary. Intere stingly, 
we didn’t reveal any correlation between NaPi2b 
protein expression and SLC34A2 mRNA expression 
in ovarian tumor samples detected by conventional 
RT-PCR analysis [29]. This contradiction could be ex-
plained in part by putative regulation of NaPi2b expres-
sion at the posttranscriptional level [32] in ovarian 
tumors or by limitation of qualitative RT-PCR analysis. 
The main purpose of this investigation was to perform 
quantitative analysis of the SLC34A2 gene expression 
by real-time polymerase chain reaction in samples 
of normal ovary and ovarian tumors.
In this study we have analysed the same tissue 
samples that were used in our previous investiga-
tion [29] and have shown a heterogeneous level 
of SLC34A2 gene expression in ovarian tumor samples 
of different histomorphological types using quantita-
tive real-time RT-PCR analysis in contrast to previ-
ous studies where conventional RT-PCR analysis 
which showed uniform expression SLC34A2 in these 
ovarian tumors has been used. mRNA expression 
of SLC34A2 in serous and endometrioid ovarian 
carcinomas, benign serous cystoadenomas as well 
as in normal ovary accurately correlated with protein 
expression level that was detected in our previous 
investigation of these tumor samples by Western-blot 
and immunohistochemical analyses. These data clear-
ly indicate that the use of quantitative analysis is more 
sensitive for studying of SLC34A2 gene expression 
profile in different types of ovarian tumor samples and 
in normal ovary. In addition, analysis of SLC34A2 gene 
expression according to tumor differentiation level 
(poor- and well-differentiated) in the endometrioid 
and serous histological types of ovarian cancer as well 
as in unspecified ovarian adenocarcinomas showed 
that SLC34A2 is up-regulated in well-differentiated 
tumors. Thus, our results are well consistent with 
our previous data about NaPi2b protein expression 
profile in different types of ovarian carcinomas and 
data reported by Rangel et al. [25] concerning the 
various SLC23A3 gene expression profile in serous 
ovarian carcinomas according to differentiation level. 
In addition to data Rangel et al. [25], we have showed 
heterogeneous SLC34A2 expression profile according 
to differential level in endometrioid tumors as well.
According to immunohistochemical analysis phos-
phate transporter protein was located predominantly 
at the surface membrane of cancer cells, but in a few 
cases cytoplasmic and nuclear localization of NaPi2b 
in ovarian cancer cells was also observed. Since NaPi2b 
function in cancer cells has not been studied so far 
we can only suggest that NaPi2b might be involved 
in transport of inorganic phosphate from the peritoneal 
cavity fluid via surface membrane of cancer cells, while 
NaPi2b function in the cytoplasm and nuclei of cancer 
cells is completely unclear. NaPi2b function in cancer 
cells should be investigated in further studies.
Thus, quantitative real-time PCR and immuno-
hystochemical analyses allowed us to investigate 
more detailed features of NaPi2b expression in dif-
ferent types of ovarian cancer. We have shown that 
SLC34A2 gene expression detected by real-time 
RT-PCR analysis is up-regulated in well-differentiated 
ovarian carcinomas that correlates with NaPi2b pro-
tein expression in cancer cells of the same tumor 
samples. Taking into account that better differenti-
ated tumors usually have better prognosis, evaluation 
of SLC34A2 gene expression could serve as a potential 
marker for ovarian cancer diagnosis and prognosis.
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